NCT04824027 Breast Elasticity Imaging During Neoadjuvant Chemotherapy
| NCT ID | NCT04824027 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Columbia University |
| Condition | Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2021-06-14 |
| Primary Completion | 2026-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2021-06-14 with a primary completion date of 2026-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
For this study, the investigators propose investigation of a new imaging technique, Harmonic Motion Imaging (HMI), and the evaluation of its potential role in prediction of breast cancer response to neoadjuvant chemotherapy (NACT). The investigators hypothesize that changes in HMI parameters will predict response to neoadjuvant systemic therapy in early-stage breast cancer.
Eligibility Criteria
Inclusion Criteria: * Women age ≥18 * Deemed eligible to receive neoadjuvant systemic therapy as per the treating physician, with the dose and schedule deemed appropriate by the treating physician. * Any stage invasive breast cancer provided the primary breast tumor size is ≥ 4 mm Exclusion criteria: * Patient is pregnant or lactating * Presence of breast implants * History of laser or radiation therapy to the affected breast
Contact & Investigator
Elisa Konofagou, PhD
PRINCIPAL INVESTIGATOR
Columbia University
Frequently Asked Questions
Who can join the NCT04824027 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04824027 currently recruiting?
Yes, NCT04824027 is actively recruiting participants. Contact the research team at ek2191@columbia.edu for enrollment information.
Where is the NCT04824027 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT04824027 clinical trial?
NCT04824027 is sponsored by Columbia University. The principal investigator is Elisa Konofagou, PhD at Columbia University. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.